Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Todos Medical Ltd (OP: TOMDF )

0.0299 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0299
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0299
Today's Range 0.0299 - 0.0299
52wk Range 0.0103 - 0.6440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19

Performance

YTD
-41.37%
-41.37%
1 Month
+149.17%
+149.17%
3 Month
+128.24%
+128.24%
6 Month
-26.54%
-26.54%
1 Year
+30.00%
+30.00%

More News

Read More
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Via NewMediaWire
Exposures COVID-19
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Via NewMediaWire
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Via NewMediaWire
Exposures COVID-19
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Via NewMediaWire
Exposures COVID-19
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid Treatment Followed by Tollovid Dietary Supplementation
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Case Study #7 in Acute and Long COVID
Via NewMediaWire
Exposures COVID-19
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Via NewMediaWire
Exposures COVID-19 Product Safety
Todos Medical Releases Preliminary Data from IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Via AB Newswire
Exposures COVID-19
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid Market Research Study in Acute and Long COVID
Via NewMediaWire
Exposures COVID-19
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Via NewMediaWire
Exposures COVID-19
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Day 45 Update for Case Study #6
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Via NewMediaWire
Exposures COVID-19
Todos Medical to Present at The LD Micro Conference
Via NewMediaWire
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer's Blood Test Clinical Validation Trial vs. Amyloid PET
Via NewMediaWire
Todos Medical Reports Day 26 Update For Case Study #4
Via NewMediaWire
Exposures COVID-19
Todos Medical Releases Corporate Update
Via NewMediaWire
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
Via NewMediaWire
Exposures COVID-19
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Via Benzinga
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Max Strength including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Via NewMediaWire
Exposures Product Safety
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Via Benzinga
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction until May 30th, 2022
Via NewMediaWire
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.